Polaryx Therapeutics targets Q4 2026 start for SOTERIA Phase 2 PLX-200 basket trial - PLYX News | RalliesPolaryx Therapeutics targets Q4 2026 start for SOTERIA Phase 2 PLX-200 basket trial
P
PLYX• SOTERIA Phase 2 trial planning and financing
- Polaryx Therapeutics outlined plans to launch its SOTERIA Phase 2 basket trial of PLX-200 in Q4 2026.
- No clinical results were presented; an interim readout is planned using 52-week maintenance data.
- The study aims to assess safety, drug exposure, tolerability, and signs of clinical activity in pediatric lysosomal storage disorders.
- The FDA cleared the trial to proceed, and PLX-200 received Fast Track Designation across the four planned indications.
- The company said it completed USD 10 million in financing to fund trial initiation and near-term clinical milestones.
